Johnson & Johnson (JNJ) Announces RYBREVANT plus LAZCLUZE approved in the U.S.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Johnson & Johnson (JNJ) to acquire V-Wave in deal worth up to $1.7bn
August 20, 2024 8:40 AM EDT(Updated - August 20, 2024 11:13 AM EDT)
Johnson & Johnson (NYSE: JNJ) announced Tuesday that it has struck an agreement to acquire V-Wave Ltd., a privately-held company specializing in treatments for heart failure.
The deal will see Johnson & Johnson make an upfront payment of $600 million, with the potential for an additional $1.1 billion in milestone payments.
V-Wave will join Johnson &... More
Johnson & Johnson gets green light for lung cancer combination treatment
August 20, 2024 7:49 AM EDTJohnson & Johnson (NYSE: JNJ) announced Tuesday that it has received U.S. Food and Drug Administration (FDA) approval for a combination treatment of RYBREVANT and LAZCLUZE for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations.
According to the company, it... More
